Skip to main
CELU

Celularity (CELU) Stock Forecast & Price Target

Celularity (CELU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celularity Inc is positioned strongly within the biotechnology sector, particularly through its development of off-the-shelf placental-derived cell therapies that address a range of medical conditions, including cancer and degenerative diseases. The company has demonstrated promising clinical results with its lead product, PDA-002, achieving ulcer closure rates of 42.8% to 53.8% at various time points, which compares favorably to existing FDA-approved treatments such as Dermagraft and Dermapace. Additionally, Celularity's majority revenue generation from its bio-banking segment underpins its financial stability, supporting further investment in innovative therapies and enhancing its growth potential.

Bears say

Celularity Inc. faces significant risks associated with manufacturing failures, which could negatively impact its clinical trials and hinder operations in both the biobanking and degenerative diseases segments. Additionally, the observed decline in NK cell function with age poses a challenge for the effectiveness of their proposed therapies, potentially limiting market opportunities for their age-related conditions. The combination of operational uncertainties and scientific limitations presents a concerning outlook for the company's overall growth and revenue generation potential.

Celularity (CELU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celularity (CELU) Forecast

Analysts have given Celularity (CELU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Celularity (CELU) has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celularity (CELU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.